Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
Summary
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10-17 years with type 2 diabetes, addressing a significan...
Description
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10-17 years with type 2 diabetes, addressing a significan...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source